Patents Represented by Attorney, Agent or Law Firm Peter J. Waibel, Esq.
  • Substituted hetero-polycyclic compounds as PPAR&agr; and PPAR&ggr; activators
    Patent number: 6468996
    Abstract: The present invention relates to compounds of the general formula (I) The compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).
    Type: Grant
    Filed: October 19, 1999
    Date of Patent: October 22, 2002
    Assignees: Novo Nordisk A/S, Dr. Reddy's Research Foundation
    Inventors: Lone Jeppesen, Paul Stanley Bury, Per Sauerberg
  • Substituted imidazoles, their preparation and use
    Patent number: 6417218
    Abstract: A class of substituted imidazole compounds of formula I methods for their preparation, pharmaceutical compositions comprising them and use thereof in the treatment of disorders related to the histamine H3 receptor are disclosed. More particularly, these compounds possess histamine H3 receptor antagonistic activity and are thus useful for the treatment of disorders in which a histamine H3 receptor blockade is beneficial.
    Type: Grant
    Filed: January 18, 2000
    Date of Patent: July 9, 2002
    Assignees: Novo Nordisk A/S, Boehringer Ingelheim International GmbH
    Inventors: Florencio Zaragoza Dorwald, Knud Erik Andersen
  • Tetrahydronaphtalene derivatives and their use
    Patent number: 6410743
    Abstract: Tetrahydronaphatalene derivatives, and compositions comprising the compounds. The tetrahydronaphatalene derivates are useful in inhibiting a rise in intracellular calcium mediated by an influx through T-type calcium channels, and are thus useful for treatment of, for example, type 1 and type 2 diabetes and cardiovascular diseases associated with diabetes.
    Type: Grant
    Filed: March 27, 2001
    Date of Patent: June 25, 2002
    Assignees: Novo Nordisk A/S, South Alabama Medical Science Foundation
    Inventors: Ming Li, John Bondo Hansen, Tina Moller Tagmose
  • Modulators of protein tyrosine phosphateses (PTPases)
    Patent number: 6410556
    Abstract: Disclosed are novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds of Formula 1 are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) including PTP1B, T cell PTP, wherein n, m, X, R1, R2, R3, R4, R5, R6, and R7 are defined more fully in the description. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, and other diseases.
    Type: Grant
    Filed: September 11, 2000
    Date of Patent: June 25, 2002
    Assignees: Novo Nordisk A/S, Ontogen Corporation
    Inventors: Henrik Sune Andersen, Thomas Kruse Hansen, Jesper Lau, Niels Peter Hundahl Møller, Ole Hvilsted Olsen, Frank Urban Axe, Yu Ge, Daniel Dale Holsworth, Todd Kevin Jones, Luke Milburn Judge, Wiliam Charles Ripka, Barry Zvi Shapira, Roy Teruyuki Uyeda
  • Modulators of protein tyrosine phosphatases (PTPases)
    Patent number: 6410586
    Abstract: The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B. CD45, SHP-1, SHP-2, PTP&agr;, LAR and HePTP or the like. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.
    Type: Grant
    Filed: March 16, 2001
    Date of Patent: June 25, 2002
    Assignees: Novo Nordisk A/S, Ontogen Corporation
    Inventors: Niels Peter Hundahl Møller, Henrik Sune Andersen, Lars Fogh Iversen, Ole Hvilsted Olsen, Sven Branner, Daniel Dale Holsworth, Farid Bakir, Luke Milburn Judge, Frank Urban Axe, Todd Kevin Jones, William Charles Ripka, Yu Ge, Roy Teruyuki Uyeda
  • Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR)
    Patent number: 6407127
    Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, Ar, X, Q, A, Y and Z are as defined in the specification. These compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).
    Type: Grant
    Filed: April 13, 2001
    Date of Patent: June 18, 2002
    Assignees: Novo Nordisk A/S, Dr. Reddy's Research foundation
    Inventors: Lone Jeppesen, Paul Stanley Bury, Per Sauerberg
  • Meiosis regulating compounds
    Patent number: 6407086
    Abstract: Certain novel sterol derivatives can be used for regulating the meiosis in oocytes and in male germ cells.
    Type: Grant
    Filed: January 12, 2001
    Date of Patent: June 18, 2002
    Assignees: Novo Nordisk A/S, Schering Aktiengesellschaft
    Inventors: Peter Faarup, Frederick Christian Grønvald, Thorsten Blume, Anthony Murray, Jens Breinholt
  • Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV
    Patent number: 6380398
    Abstract: Described are compounds of formula I wherein at least one of the bonds in the five-membered ring is a double bond; B is any alpha or beta amino acid connected to the ring with an amide or peptide bond; or a salt thereof with a pharmaceutically acceptable acid or base. Pharmaceutical compositions containing these compounds are also described. These compounds are useful for treating type II diabetes.
    Type: Grant
    Filed: January 23, 2001
    Date of Patent: April 30, 2002
    Assignee: Novo Nordisk A/S
    Inventors: Anders Kanstrup, Jane Marie Lundbeck, Lise Brown Christiansen
  • Compounds, their preparation and use
    Patent number: 6369055
    Abstract: The present invention relates to compounds of the general formula (I) The compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).
    Type: Grant
    Filed: April 18, 2000
    Date of Patent: April 9, 2002
    Assignee: Novo Nordisk A/S
    Inventors: Lone Jeppesen, Per Sauerberg, Anthony Murray, Paul Stanley Bury
  • Compounds, their preparation and use
    Patent number: 6365586
    Abstract: The present invention relates to compounds of the general formula (I) The compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).
    Type: Grant
    Filed: October 19, 1999
    Date of Patent: April 2, 2002
    Assignees: Novo Nordisk A/S, Dr. Reddy's Research Foundation
    Inventors: Lone Jeppesen, Paul Stanley Bury, Per Sauerberg
  • Substituted 3,3-diamino-2-propenenitriles, their preparation and use
    Patent number: 6365609
    Abstract: Described are substituted cyanoenamines of formula I wherein Z, R1, R2 and R3 are defined in the description, compositions thereof and methods for preparing these compounds. These compounds are useful in the treatment of diseases of the central nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinologic system.
    Type: Grant
    Filed: September 22, 2000
    Date of Patent: April 2, 2002
    Assignee: Novo Nordisk A/S
    Inventors: John Bondo Hansen, Tina Moller Tagmose, John Patrick Mogensen, Florencio Zaragoza Dorwald, Anker Steen Jorgensen
  • Substituted 3,3-diamino-2-propenenitriles, their preparation and use
    Patent number: 6362205
    Abstract: Described are substituted cyanoenamines of formula I wherein Z, R1, R2 and R3 are defined in the description, compositions thereof and methods for preparing these compounds. These compounds are useful in the treatment of diseases of the central nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinologic system.
    Type: Grant
    Filed: March 16, 2001
    Date of Patent: March 26, 2002
    Assignee: Novo Nordisk A/S
    Inventors: John Bondo Hansen, Tina Moller Tagmose, John Patrick Mogensen, Florencio Zaragoza Dorwald, Anker Steen Jorgensen
  • Compounds, their preparation and use
    Patent number: 6353018
    Abstract: The present invention relates to compounds of the general formula (I) The compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).
    Type: Grant
    Filed: October 19, 1999
    Date of Patent: March 5, 2002
    Assignees: Novo Nordisk A/S, Dr. Reddy's Research Foundation
    Inventors: Lone Jeppesen, Paul Stanley Bury, Per Sauerberg